Liminatus Pharma, Inc.
LIMN
$0.65
-$0.06-8.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.27M | -1.04M | -3.55M | -3.55M | -4.09M |
| Total Depreciation and Amortization | 1.20K | 700.00 | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -166.30K | -1.27M | -- | -- | -- |
| Change in Net Operating Assets | -7.29M | -7.01M | 2.09M | 2.09M | 2.46M |
| Cash from Operations | -9.72M | -9.32M | -1.45M | -1.45M | -1.63M |
| Capital Expenditure | -13.10K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.33M | -2.13M | -2.85M | -2.85M | -2.77M |
| Cash from Investing | -1.34M | -2.13M | -2.85M | -3.55M | -3.47M |
| Total Debt Issued | 5.04M | 6.02M | 3.92M | 3.92M | 4.62M |
| Total Debt Repaid | -1.30M | -1.30M | -- | -- | -200.00K |
| Issuance of Common Stock | 10.56M | 10.56M | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.56M | -2.53M | 0.00 | 0.00 | 0.00 |
| Cash from Financing | 11.73M | 12.75M | 3.92M | 5.09M | 5.59M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 677.20K | 1.30M | -378.40K | -786.40K | -383.40K |